Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO 2025 Breast Cancer Highlights
Featuring presentations & discussions on selected breast cancer abstracts from the 2025 American Society of Clinical Oncology (ASCO) annual meeting.
Chair: Eva Ciruelos | Moderators: Lisa Carey, Marleen Kok
Session 1: Advances in hormone-receptor-positive breast cancer
Updated survival outcomes and predictors of benefit from ovarian function suppression in premenopausal women with hormone-receptor–positive breast cancer: Results from the ASTRRA trial
Jai Min Ryu Samsung Medical Center, Seoul, Korea, Republic of
Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study
Erika Hamilton Sarah Cannon Cancer Center, Nashville, TN, United States
Panel discussion
Session 2: Latest with ADCs and HER2-directed therapy
Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09
Sara Tolaney Dana Farber Cancer Institute, Boston, MA, United States
Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study
Sara Tolaney Dana Farber Cancer Institute, Boston, MA, United States
Panel discussion
Session 3: Chemotherapy optimization and DNA damage response targeting
Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364)
Sung-Bae Kim Asan Medical Center, Korea, Republic of
Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial
Christian Singer Medical University of Vienna, Vienna, Austria
Panel discussion
